Will This New Technology Put Trains & Airlines Out Of Business?
Whitney Tilson: An incredible new technology could soon get me from my home in Manhattan to Washington DC for as little as $25!

This is likely to make a lot of people rich.

Click here for my analysis, where I include the stock and ticker symbol of my #1 way to play it.
>>>

CYTH Insider Trading (Cyclo Therapeutics)

Insider Ownership Percentage: 12.30%
Insider Buying (Last 12 Months): $535,328.70
Insider Selling (Last 12 Months): $0.00

Cyclo Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Share Price & Price History

Current Price: $4.24
Price Change: Price Decrease of -0.26 (-5.78%)
As of 01/14/2022 01:00 AM ET

This chart shows the closing price history over time for CYTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
5 Free Dividend Stocks for 2022
Could these top payout stocks be part of the greatest wealth-creating tool in history?
Learn More.

Cyclo Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/14/2022Francis Patrick OstronicDirectorBuy2,137$4.00$8,548.00View SEC Filing Icon  
12/15/2021Francis Patrick OstronicDirectorBuy3,000$3.90$11,700.00View SEC Filing Icon  
12/15/2021N. Scott FineCEOBuy5,000$3.89$19,450.00View SEC Filing Icon  
12/3/2021Francis Patrick OstronicDirectorBuy864$4.75$4,104.00View SEC Filing Icon  
12/2/2021Sharon Hemond HrynkowInsiderBuy1,000$4.98$4,980.00View SEC Filing Icon  
12/1/2021Francis Patrick OstronicDirectorBuy5,000$5.00$25,000.00View SEC Filing Icon  
11/19/2021Francis Patrick OstronicDirectorBuy10,652$5.25$55,923.00View SEC Filing Icon  
11/19/2021N. Scott FineCEOBuy5,000$5.25$26,250.00View SEC Filing Icon  
10/29/2021Francis Patrick OstronicDirectorBuy1,000$5.90$5,900.00View SEC Filing Icon  
9/15/2021N. Scott FineCEOBuy5,000$6.35$31,750.00114,666View SEC Filing Icon  
4/16/2021Francis Patrick OstronicDirectorBuy10,000$6.53$65,300.0071,559View SEC Filing Icon  
4/12/2021Francis Patrick OstronicDirectorBuy5,000$7.00$35,000.00
3/29/2021Jeffrey TateCOOBuy2,000$7.50$15,000.0027,160View SEC Filing Icon  
3/29/2021Joshua M. FineCFOBuy50$7.40$370.0016,900View SEC Filing Icon  
3/29/2021Markus SiegerDirectorBuy10,000$8.10$81,000.0059,559View SEC Filing Icon  
3/29/2021Markus SiegerDirectorBuy10,000$8.10$81,000.0067,614View SEC Filing Icon  
3/29/2021Sharon Hemond HrynkowInsiderBuy1,000$7.46$7,460.0018,350View SEC Filing Icon  
3/29/2021Sharon Hemond HrynkowInsiderBuy1,000$7.46$7,460.0018,350View SEC Filing Icon  
1/25/2021Markus SiegerDirectorBuy7,799$6.30$49,133.70View SEC Filing Icon  
12/17/2020Francis Patrick OstronicDirectorBuy30,000$4.66$139,800.00
See Full Table
Insider Selling at Cyclo Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Cyclo Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Cyclo Therapeutics (NASDAQ:CYTH)

5.13% of Cyclo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CYTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cyclo Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2021Two Sigma Advisers LP12,200$82K0.0%N/A0.189%Search for SEC Filing on Google Icon
11/16/2021UBS Group AG39,914$0.27M0.0%+259.8%0.620%Search for SEC Filing on Google Icon
11/12/2021Geode Capital Management LLC51,454$0.35M0.0%+20.8%0.799%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.13,134$88K0.0%+21.1%0.204%Search for SEC Filing on Google Icon
8/16/2021State Street Corp44,700$0.46M0.0%N/A0.703%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC42,577$0.44M0.0%+133.2%0.670%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.151,540$1.55M0.0%+350.4%2.383%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC18,257$0.15M0.0%N/A0.287%Search for SEC Filing on Google Icon
3/26/2021Susquehanna International Group LLP15,656$68K0.0%N/A0.249%Search for SEC Filing on Google Icon
2/17/2021Jane Street Group LLC27,892$0.12M0.0%N/A1.641%Search for SEC Filing on Google Icon
2/17/2021Worth Venture Partners LLC88,690$0.39M0.3%N/A5.217%Search for SEC Filing on Google Icon
2/16/2021Armistice Capital LLC100,000$0.44M0.0%N/A5.882%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cyclo Therapeutics logo
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Read More on Cyclo Therapeutics

Today's Range

Now: $4.24
Low: $4.00
High: $4.50

50 Day Range

MA: $4.82
Low: $3.47
High: $7.34

52 Week Range

Now: $4.24
Low: $3.43
High: $17.75

Volume

139,510 shs

Average Volume

130,190 shs

Market Capitalization

$27.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Cyclo Therapeutics?

Cyclo Therapeutics' top insider investors include:
  1. N Scott Fine (CEO)
  2. Francis Patrick Ostronic (Director)
  3. Markus Sieger (Director)
  4. Jeffrey Tate (COO)
  5. Sharon Hemond Hrynkow (Insider)
  6. Joshua M Fine (CFO)
“Move your money by early 2022,” Wall Street legend warns
A new form of technology will cause a massive shift in the wealth divide in 2022. Do you own the stocks that will be affected?
Details here…